Capital to Cure: Navigating the Life Sciences Funding Journey

In Life Science & MedTech, investors evaluate startups by science, timing, team, risk, and exit potential from Pre-Seed to Series B/C.

Join us on 25 June 2026 at 5:00 PM at INiTS in Vienna for an exclusive panel discussion followed by a moderated Q&A and networking session. The event brings together leading investors from across the financing spectrum from early stage backers to later stage venture capital firms offering candid insights into how investment decisions are really made.

The discussion will focus on how expectations evolve as companies mature, what investors look for at each stage, and how founders can approach fundraising more strategically and effectively.

Investment Managers

• Guido Boehmelt from Curie.bio
• Juri Bach from High-Tech Gründerfonds
• Laura Pedroza from Abbvie Ventures
• Paul Sunzenauer from Occident

Moderation: Markus Pietzka (INiTS)

Topics we’ll explore

• How investors determine when a Life Science or MedTech idea becomes investable including early red flags “minimum traction” and how diligence evolves from Seed to Series A and beyond
• How different investor types think (angels vs seed VCs) and where value is created across the investment lifecycle
• What Series B/C investors prioritize including the balance between growth profitability and exit strategy
• How venture capital works at fund level including portfolio construction and why a small number of breakout companies drive most returns
• How macroeconomic and geopolitical conditions influence investment appetite and portfolio management in practice

Additional information

• Privacy notice: By attending this event you agree that photos and videos may be taken and used for communication purposes.
• No-show policy: Cancellations made less than 24 hours before the event start time or non-attendance without prior cancellation will incur a EUR 50 (excl. VAT) no-show fee for free tickets. For paid tickets no refunds apply in such cases.